April 2025 in “International Journal of Dermatology” This abstract does not report any research results but mentions researcher affiliations and potential conflicts of interest, indicating the researchers' involvement in various pharmaceutical collaborations.
January 2024 in “Journal of Crohn's and colitis” This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.
June 2023 in “Fundamental & clinical pharmacology” This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.
January 2024 in “Wiadomości Lekarskie” In this study, researchers examined a patient with ZMYM2::FGFR1 fusion-positive leukemia, finding that Pemigatinib showed efficacy, while Ponatinib resistance was linked to a specific FGFR1 mutation. Other FGFR inhibitors demonstrated high effectiveness in ex vivo assays.
44 citations
,
April 2006 in “Expert opinion on drug safety” This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.